Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Apixaban.
- Who it may be relevant to
- Registry conditions: Nonvalvular Atrial Fibrillation. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Bosnia and Herzegovina
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Monitoring Safety and Therapeutic Adherence During Anticoagulant Prophylaxis With Apixa® in Patients With Nonvalvular Atrial Fibrillation (Praćenje Sigurnosti i Terapijske Adherence u Toku Antikoagulantne Profilakse Lijekom Apixa® Kod Pacijenata sa Nevalvularnom Atrijalnom Fibrilacijom)
Overview
The aim of this observational study is to evaluate safety and therapeutic adherence during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation. The main questions it aims to answer are: * What is the incidence of major bleeding and clinically relevant non-major bleeding during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation? * What is therapy adherence during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation? * What is frequency and types of other adverse reactions, excluding bleeding, during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation? Participants will be followed for six months through four measurements. The first and fourth measurements will be performed in person, while the remaining measurements can also be recorded by telephone, if the patient's condition allows. Any bleeding or serious adverse reactions to the medication being administered will be recorded immediately, through unscheduled measurements. Adverse reactions will be recorded at each measurement. Adherence to the medication being administered will be evaluated using the BARS scale.
Interventions
- Drug Apixaban
Patients will receive orally 5 mg of apixaban twice daily or reduced dose 2.5 mg, twice a day orally, in patients with at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg or serum creatinine ≥ 1.5 mg/dl (133 μmol/l).
Primary outcome measures
- Composite primary outcome including incidence of major bleeding and clinically relevant non-major bleeding [Time frame: From enrollment to the end of study after six months]
Secondary outcome measures (3)
- Monitoring of adherence to anticoagulant prophylaxis [Time frame: From enrollment to the end of study after six months]
- Monitoring the composite outcome of major, clinically relevant non-major and minor bleeding [Time frame: From enrollment to the end of study after six months]
- Monitoring the frequency and type of other adverse reactions, excluding bleeding [Time frame: From enrollment to the end of study after six months]
Eligibility criteria
Inclusion criteria
- Patients over 18 years of age.
- Hemodynamically stable patients.
- Patients with non-valvular atrial fibrillation.
- Patients in whom the investigator, based on clinical assessment makes a decision to introduce apixaban therapy.
- Patients who are on apixaban therapy for the first time
Exclusion criteria
- Positive history of angioneurotic edema.
- Active, clinically significant bleeding.
- Congenital or acquired bleeding disorder.
- The presence of a malignant tumor.
- Current or recent presence of gastrointestinal ulcer.
- The presence of established or suspected esophageal varices.
- Positive history of arteriovenous malformations, vascular aneurysms or intraspinal and intracerebral vascular anomalies.
- Patients with artificial heart valves.
- Liver cirrhosis and active liver disease associated with coagulopathy and clinically significant risk of bleeding.
- Dialysis patients (GFR <15 ml/min).
- Simultaneous use of other anticoagulants.
- Pregnancy and breastfeeding.
- Patients who previously used apixaban in therapy.
Withdrawal Criteria:
- Deterioration of the clinical picture of the underlying disease that requires discontinuation of investigational therapy.
- Development of serious adverse events that require discontinuation of therapy.
- Occurrence of pregnancy.
- Development of another disease that affects the course of research.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Bosnia and Herzegovina · 1 center
- Clinic for diseases of the heart, blood vessels and rheumatism — Sarajevo
Identifiers
NCT: NCT07458191 · APX-01-2025